#RadOnc @Sunnybrook @UofTDRO. Likes: 🍣 🎾 ⚽️. Dislikes: cancers. Tweets are my own.
Toronto, Ontario
Joined July 2020
- Tweets149
- Following135
- Followers219
- Likes354
Michael Tjong retweeted
💥Game-changer in small cell #lungcancer! #ESMO26 LBA3 DeLLphi-305: Tarlatamab + durvalumab vs durvalumab 1L maintenance in ES-SCLC (n=563) after chemo-IO. Median OS ⬆️ 21.1 vs 12.7 mo (HR 0.42), PFS ⬆️7.4 vs 1.9 mo (HR 0.34), ORR 26% vs 4%. ☢️44% of pts still on T+D due to #radiotherapy of oligoprogressive sites? #SCLC #LCSM @NEJM ➡️ shorturl.at/IiOO1
Michael Tjong retweeted
Now in @JAMAOnc:
We report 5y outcomes post 30 Gy elective RT (total 70 Gy CCRT) for 276 pts w/ HPV-related OPC #hncsm at @MSKCancerCenter #radonc
LRC 97.0%
OS 90.8%
PFS 85.9%
DMFS 91.2%
@imrtlee @xrtGenomics @seanmmcbride @CJTsaiMDPhD @EChrisDee
👉 shorturl.at/liqpP
Michael Tjong retweeted
Today at #ASCO26: MSK radiation oncologist Dr. Nancy Lee (@imrtlee) shared long-term results showing that many patients with HPV-positive #oropharyngeal cancer were able to receive lower-dose radiation while maintaining durable outcomes and experiencing fewer side effects.
Michael Tjong retweeted
Kudos to our @Sunnybrook medical physics, electronics and therapy team as we have successfully installed the Varian ETHOS as the 1st of 2 matched units. Critical step as we transform our department to realize the Cancer Ablation Adaptive Therapy (CAAT) Program mission.
Michael Tjong retweeted
#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm
1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months.
2) 100% Cancer-Specific Survival
3) Grade 3 AEs remain at 10%
Michael Tjong retweeted
Absolutely terrific work by @DrSymYoung to report the long-term outcomes of our INRT experience from two prospective trials (INRT-AIR and DARTBOARD).
Short version: with long-term follow-up (median 5.2 years for INRT-AIR, 3 years for DARTBOARD), we've seen zero solitary elective nodal recurrences.
Longer version: ESTRO has highlighted novel approaches to managing the elective neck in HNSCC, and I believe the future will be very different than the present. Current ENI fields deliver the majority of the integral dose to patients and contribute substantially to critical structures (swallowing and xerostomia OARs). Minimizing ENI dose and volume may meaningfully improve the short- and especially long-term tolerance of radiotherapy.
A few more thoughts on our INRT paradigm below:
Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Omission of elective nodal irradiation in HNSCC: long-term results and patient-level pooled analysis from 2 prospective trials (INRT-AIR & DARTBOARD)
Presenter Sympascho Young 🇺🇸
A patient-level pooled analysis of 117 patients from two prospective trials (INRT-AIR and DARTBOARD) showed that omission of elective nodal irradiation for HNSCC was oncologically safe long-term, with a 0% rate of solitary elective nodal recurrence at 5 years. The trials used an involved nodal radiotherapy (INRT) approach assisted by an artificial intelligence model for detection of suspicious nodes.
@DrSymYoung @DavidSherMD
#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72
Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth
Michael Tjong retweeted
Great letter by @SeanMcbride laying out real concerns with the OS claim in @SJFrankMD's proton vs. photon oropharynx trial. Compelling enough that Yingzhi Wu and @EChrisDee pulled our own data. We see no OS difference between protons and photons. Together with UK TORPEdO RCT, this adds to the concern that the randomized trial’s OS finding may be hypothesis-generating rather than causal.
Our letter to the editor in The Lancet critiquing the MD Anderson-led trial of protons v photons for OPC. Appreciate @SJFrankMD's well thought out response.
I think we can all agree on two points:
1) Steve deserves major kudos for bringing level 1 evidence to the debate on protons v photons for OPC. These trials are extraordinarily difficult to run, and Steve, et al pulled it off. Well done!
2) Longer term follow-up from TORPEdO will help tease out the extent to which protons improves OS in OPC.
@CJTsaiMDPhD @drlorenmell @xrtGenomics @DavidSherMD #radonc #hncsm
thelancet.com/journals/lance…
Michael Tjong retweeted
Excited to share our publication in @TheLancetOncol on the primary results from the UNITED study: a new paradigm in radiotherapy for patients with glioblastoma /1 @Sunnybrook @UofTDRO thelancet.com/journals/lanon…
Michael Tjong retweeted
A blast to have @imrtlee (@MSKCancerCenter) as our @Sunnybrook #radonc Dembo Visiting Professor share her vision + trailblazing path towards personalization of cancer care. A beacon of joy and creativity in head & neck cancer and beyond! @SahgalArjun @mctjong @UofTDRO @ldawsonmd
Michael Tjong retweeted
The entire @Sunnybrook spine #SBRT team has come together to share 17 years of research and clinical observations in this review for @NatRevClinOncol. We are a true multidisciplinary team that have had a singular focus to develop the technique and evidence nature.com/articles/s41571-0…
Michael Tjong retweeted
📌 Cardiac Dose and Survival Outcomes Following SBRT for Primary and Metastatic Lung Tumors: A Substructure-Based Analysis
🔗 advancesradonc.org/article/S…
@ASTRO_org @ChariteBerlin
👉🏻 Dose–response relationships are driven by cardiac substructures rather than by whole-heart exposure.
👉🏻Elevated EQD₂ doses to upper cardiac structures, such as the left atrium and superior vena cava, were independently associated with reduced overall survival.
👉🏻 There was a trend toward decreased survival with higher doses to the cardiac base, indicating a consistent vulnerability of this region.
Michael Tjong retweeted
🔥 Hot off the press: "Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT"
➡️In T2N0 glottic cancer, impaired vocal cord mobility is associated with worse LRF (aHR 3.7) and DFS (aHR 2.7)
doi.org/10.1002/lary.70424
@PMResearch_UHN @UofTDRO
Michael Tjong retweeted
🫁 International practice patterns for radiation planning and treatment of limited stage small cell lung cancer (LS-SCLC)🫁
🗣️Calling on the #lcsm #radonc community to participate in this survey from our team led by @UofTDRO @Sunnybrook @DrAlexLouie (PI) and Neelabh Rastogi (PGY-3 Resident)
Study link and QR code below: surveymonkey.com/r/CYCCYC2
@drdavidpalma @mctjong @SALfaifi_
Michael Tjong retweeted
Similar model in last few years at @Sunnybrook #hncsm #radonc (not just NPC) w/ 1:1 RD + MD pairing from pre-treatment through follow-up with proactive weekly RD assessments during on-treatment review visits. Requires support as volumes and team grow but a worthwhile venture.
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
Michael Tjong retweeted
Honored to support the very first World Radiotherapy Awareness Day today, September 7th! 🌍
By working together, we can ensure every person facing cancer has access to life-saving radiotherapy.
#WorldRTDay @CamdenClarkMC
📚 Learn more: worldradiotherapy.org
Michael Tjong retweeted
☢️ Finally published the High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy for LS-SCLC.
✅OS 43.5 versus 22.5 mo, (HR 0.68, 95% CI 0.48–0.98, p = 0.037)
No more acute or late onset toxicity.
✅ Would you now consider 60 Gy bid the new standard of care?
#LCSM @SclcSMASHERS
ovid.com/journals/jton/abstr…
Michael Tjong retweeted
Nasser Altorki's team publishes new data investigating the role of preop SBRT for NSCLC. This time, reporting their institutional data comparing preop SBRT-IO vs Chemo-IO. The results demonstrate a significant association with improved RFS at 2 years with SBRT delivered BEFORE immunotherapy (92% vs 64%, HR = 0.19). Technique = 8 Gy x 3, omiting the LNs doi.org/10.1016/j.jtcvs.2025…
Michael Tjong retweeted
New data from the randomized PEMBRO-RT study demonstrate when an ICI-mediated Abscopal effect is most likely to occur in patients with stage IV NSCLC. @rweichselbaum @SeanPitroda @dramycummings doi.org/10.1038/s43018-025-0…
Michael Tjong retweeted
It hit home as I returned to @Sunnybrook, where my own mother received cancer treatment with a message of HOPE to all who fight this disease.
To help the more than 247,000 Canadians this year alone who will be diagnosed with cancer, I was proud to announce an ambitious plan to double the production of life-saving medical isotopes by 2030.
Nuclear isotopes produce the essential treatments that help to destroy tumors and diagnose cancers earlier.
The Nuclear Isotope Innovation Council of Ontario will save lives and create jobs — a legacy we can all get behind.
